We are live on ! Find out more
VIA

Virtus Investment Advisers Portfolio holdings

AUM $429M
1-Year Est. Return 52.52%
This Fund
S&P 500
This Quarter Est. Return
+23.54%
1 Year Est. Return
+52.52%
3 Year Est. Return
+172.32%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$429M
AUM Growth
+$66.7M
Cap. Flow
+$19.4M
Cap. Flow %
4.52%
Top 10 Hldgs %
7.64%
Holding
517
New
67
Increased
228
Reduced
168
Closed
54

Top Buys

Rank Stock Value
1
DVN icon
Devon Energy
DVN
+$3.47M
2
DDOG icon
Datadog
DDOG
+$2.53M
3
MRVL icon
Marvell Technology
MRVL
+$2.28M
4
WDC icon
Western Digital
WDC
+$2.19M
5
NTAP icon
NetApp
NTAP
+$2.17M

Top Sells

Rank Stock Value
1
DAWN
Day One Biopharmaceuticals
DAWN
+$2.17M
2
LIN icon
Linde
LIN
+$2.08M
3
HSY icon
Hershey
HSY
+$2.06M
4
LYV icon
Live Nation Entertainment
LYV
+$1.97M
5
KO icon
Coca-Cola
KO
+$1.96M

Sector Composition

Rank Sector Weight
1 Healthcare 38.77%
2 Technology 15.15%
3 Financials 13.21%
4 Industrials 12.74%
5 Consumer Discretionary 5.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ORKA
226
Oruka Therapeutics
ORKA
$6.16B
$445K 0.1%
4,681
-4,353
-48% -$290K
BIOA
227
BioAge Labs
BIOA
$373M
$445K 0.1%
+18,137
New +$328K
VKTX icon
228
Viking Therapeutics
VKTX
$3.49B
$444K 0.1%
11,381
+4,027
+55% +$130K
JFR icon
229
Nuveen Floating Rate Income Fund
JFR
$1.2B
$441K 0.1%
57,539
-16,826
-23% -$127K
PFLT icon
230
PennantPark Floating Rate Capital
PFLT
$699M
$441K 0.1%
58,934
-16,080
-21% -$134K
ATAI
231
DELISTED
AtaiBeckley Inc
ATAI
$440K 0.1%
83,469
+19,906
+31% +$83.8K
JQC icon
232
Nuveen Credit Strategies Income Fund
JQC
$690M
$436K 0.1%
89,789
-23,888
-21% -$115K
KYMR icon
233
Kymera Therapeutics
KYMR
$9.54B
$435K 0.1%
3,795
+755
+25% +$64.9K
PRME icon
234
Prime Medicine
PRME
$575M
$435K 0.1%
117,909
+51,401
+77% +$171K
CGEM icon
235
Cullinan Oncology
CGEM
$1.31B
$435K 0.1%
23,883
+1,008
+4% +$15K
GLUE icon
236
Monte Rosa Therapeutics
GLUE
$1.09B
$434K 0.1%
17,944
+1,226
+7% +$23.2K
MFIC icon
237
MidCap Financial Investment
MFIC
$750M
$434K 0.1%
43,045
-12,167
-22% -$134K
KIO
238
KKR Income Opportunities Fund
KIO
$440M
$432K 0.1%
38,341
-10,232
-21% -$115K
BHVN icon
239
Biohaven
BHVN
$1.85B
$432K 0.1%
29,007
+5,357
+23% +$57.7K
DSGN icon
240
Design Therapeutics
DSGN
$791M
$432K 0.1%
+29,827
New +$372K
ORIC icon
241
Oric Pharmaceuticals
ORIC
$1.29B
$428K 0.1%
39,565
+10,496
+36% +$95.2K
XNCR icon
242
Xencor
XNCR
$1.77B
$427K 0.1%
26,537
+10,031
+61% +$125K
ERAS icon
243
Erasca
ERAS
$5.54B
$427K 0.1%
23,288
-52,458
-69% -$750K
SANA icon
244
Sana Biotechnology
SANA
$943M
$426K 0.1%
122,089
+69,037
+130% +$222K
RZLT icon
245
Rezolute
RZLT
$399M
$425K 0.1%
81,800
-69,692
-46% -$259K
BXSL icon
246
Blackstone Secured Lending
BXSL
$5.78B
$424K 0.1%
17,889
-5,814
-25% -$139K
BGT icon
247
BlackRock Floating Rate Income Trust
BGT
$320M
$424K 0.1%
39,777
-10,542
-21% -$114K
RCUS icon
248
Arcus Biosciences
RCUS
$3.18B
$424K 0.1%
13,748
+1,084
+9% +$26.8K
MPLT
249
MapLight Therapeutics
MPLT
$552M
$423K 0.1%
+11,791
New +$339K
IDYA icon
250
IDEAYA Biosciences
IDYA
$3.62B
$421K 0.1%
11,290
+3,276
+41% +$100K
8 9
10
11 12

Similar funds

MSG
Main Street Group Glen Allen, Virginia $429M AUM 34.03% 1-Year Est. Return
NL
Navalign LLC Encino, California $429M AUM 18.12% 1-Year Est. Return
PG
Prostatis Group Hanover, Maryland $429M AUM 26.55% 1-Year Est. Return
LFGO
Legacy Financial Group (Oklahoma) Tulsa, Oklahoma $429M AUM 21.51% 1-Year Est. Return
SFWC
Strategic Family Wealth Counselors Fairfield, New Jersey $430M AUM 17.41% 1-Year Est. Return
RS
Rakuten Securities Tokyo, Japan $430M AUM 189.97% 1-Year Est. Return
T
TrueFG Cedar Park, Texas $428M AUM 21.6% 1-Year Est. Return
WBC
West Branch Capital Amherst, Massachusetts $430M AUM 41.9% 1-Year Est. Return

Virtus Investment Advisers's Q2 2026 Portfolio in Review

As of Q2 2026, Virtus Investment Advisers held 517 positions worth $429M, up 18% from $363M the previous quarter. Its ten largest holdings account for 7.6% of the portfolio.

Virtus Investment Advisers deployed $19.4M of net new capital in Q2 2026, opening 67 new positions and adding to 228 existing holdings. Its largest new stake was Devon Energy: 74,863 shares worth $3.09M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, up from 32% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was ImmunityBio, an estimated $1.47M trimmed.

  • Virtus Investment Advisers's largest Q2 2026 buy was Devon Energy: 74,863 shares worth $3.09M.
  • Virtus Investment Advisers added most to Omeros in Q2 2026, an estimated $1.26M increase.
  • Virtus Investment Advisers's biggest Q2 2026 reduction was ImmunityBio, cutting an estimated $1.47M.
  • Virtus Investment Advisers fully exited Day One Biopharmaceuticals in Q2 2026, selling an estimated $2.17M.
  • Virtus Investment Advisers's ten largest holdings make up 7.6% of its $429M portfolio in Q2 2026.
  • Virtus Investment Advisers opened 67 new positions and closed 54 in Q2 2026.
  • Virtus Investment Advisers's portfolio value rose 18% quarter-over-quarter to $429M.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.